When disease extent is not always a key parameter: Management of refractory ulcerative proctitis
Αbstract: Background: Patients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases. Objectives:...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Current Research in Pharmacology and Drug Discovery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257121000584 |
| _version_ | 1811187180756795392 |
|---|---|
| author | Georgios Michalopoulos Konstantinos Karmiris |
| author_facet | Georgios Michalopoulos Konstantinos Karmiris |
| author_sort | Georgios Michalopoulos |
| collection | DOAJ |
| description | Αbstract: Background: Patients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases. Objectives: To summarize available evidence on the management of refractory ulcerative proctitis and provide insights in treatment options. Results: /Conclusion: Topical therapy plays a central role due to the location of the disease. However, well-established treatment options may become exhausted in a considerable proportion of ulcerative proctitis patients, indicating the need to advance to more potent therapies in order to induce and maintain clinical response and remission in these refractory cases. Systemic corticosteroids, thiopurines, calcineurin inhibitors, biologic agents and small molecules have all been tested with variable success rates. Investigational interventions as well as surgical procedures are kept as the ultimate resort in multi-treatment resistant cases. Identifying early prognostic factors that herald a disabling disease progression will help in optimizing treatment and avoiding surgery. |
| first_indexed | 2024-04-11T13:59:04Z |
| format | Article |
| id | doaj.art-36eca9f9c3674e1aad000cac46a0d66f |
| institution | Directory Open Access Journal |
| issn | 2590-2571 |
| language | English |
| last_indexed | 2024-04-11T13:59:04Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Pharmacology and Drug Discovery |
| spelling | doaj.art-36eca9f9c3674e1aad000cac46a0d66f2022-12-22T04:20:11ZengElsevierCurrent Research in Pharmacology and Drug Discovery2590-25712022-01-013100071When disease extent is not always a key parameter: Management of refractory ulcerative proctitisGeorgios Michalopoulos0Konstantinos Karmiris1Departments of Gastroenterology, Tzaneion General Hospital, Leoforos Afentouli, 18536, Piraeus, GreeceDepartments of Gastroenterology, Venizeleio General Hospital, Knosos Avenue, P.O.Box 44, 71409, Heraklion, Crete, Greece; Corresponding author.Αbstract: Background: Patients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases. Objectives: To summarize available evidence on the management of refractory ulcerative proctitis and provide insights in treatment options. Results: /Conclusion: Topical therapy plays a central role due to the location of the disease. However, well-established treatment options may become exhausted in a considerable proportion of ulcerative proctitis patients, indicating the need to advance to more potent therapies in order to induce and maintain clinical response and remission in these refractory cases. Systemic corticosteroids, thiopurines, calcineurin inhibitors, biologic agents and small molecules have all been tested with variable success rates. Investigational interventions as well as surgical procedures are kept as the ultimate resort in multi-treatment resistant cases. Identifying early prognostic factors that herald a disabling disease progression will help in optimizing treatment and avoiding surgery.http://www.sciencedirect.com/science/article/pii/S2590257121000584Inflammatory bowel diseaseProctitisUlcerative colitis |
| spellingShingle | Georgios Michalopoulos Konstantinos Karmiris When disease extent is not always a key parameter: Management of refractory ulcerative proctitis Current Research in Pharmacology and Drug Discovery Inflammatory bowel disease Proctitis Ulcerative colitis |
| title | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
| title_full | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
| title_fullStr | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
| title_full_unstemmed | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
| title_short | When disease extent is not always a key parameter: Management of refractory ulcerative proctitis |
| title_sort | when disease extent is not always a key parameter management of refractory ulcerative proctitis |
| topic | Inflammatory bowel disease Proctitis Ulcerative colitis |
| url | http://www.sciencedirect.com/science/article/pii/S2590257121000584 |
| work_keys_str_mv | AT georgiosmichalopoulos whendiseaseextentisnotalwaysakeyparametermanagementofrefractoryulcerativeproctitis AT konstantinoskarmiris whendiseaseextentisnotalwaysakeyparametermanagementofrefractoryulcerativeproctitis |